The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Catalyst Trusteeship Ltd, acting as Debenture Trustee, has reported the creation of an additional pledge over 28,36,811 equity shares (2.47%) of OneSource Specialty Pharma Ltd by Tenshi Pharmaceuticals Pvt Ltd. The pledge was created in multiple tranches between January 29, 2026 and March 27, 2026 to secure zero-coupon, unlisted, redeemable non-convertible debentures of up to ₹1,000 crore issued by Karuna Ventures Pvt Ltd, a group company of the pledgor. With this, the total shares pledged with the trustee now stand at 92,36,811 shares, or 8.06% of the company's paid-up share capital. Tenshi Pharmaceuticals continues to hold 2,10,89,714 shares (18.4%) in the company, and the pledgor is not classified as a promoter. The debenture trustee has no direct voting rights on the pledged shares.
This is a financing-related encumbrance by a non-promoter shareholder to back group-level borrowing, not a change in ownership or promoter stake. Shareholders should note that 8.06% of the company's equity is now pledged as collateral, which could create overhang risk if the borrowing entity defaults, but the equity base of the company remains unchanged.